Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study

Naval G. Daver, Pau Montesinos, Daniel J. DeAngelo, Eunice S. Wang, Nikolaos Papadantonakis, Elisabetta Todisco, Kendra L. Sweet, Naveen Pemmaraju, Andrew A. Lane, Laura Torres-Miñana, James E. Thompson, Marina Konopleva, Callum M. Sloss, Krystal Watkins, Gaurav Bedse, Yining Du, Kara E. Malcolm, Patrick A Zweidler-McKay, Hagop M Kantarjian

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences